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The involvement of the ubiquitin–proteasome pathway in the degradation of critical
intracellular regulatory proteins suggested a few years ago the potential use of proteasome
inhibitors as novel therapeutic agents being applicable in many diﬀerent disease indications,
and in particular for cancer therapy. This article reviews recent salient medicinal chemistry
achievements in the design, synthesis, and biological characterization of both synthetic and
natural peptide-like proteasome inhibitors, updating recent reviews on this class of agents. As
shown herein, diﬀerent compound classes are capable of modulating the subunit-speciﬁc
proteolytic activities of the 20S proteasome in ways not previously possible, and one of them,
bortezomib, has provided proof-of-concept for this therapeutic approach in cancer clinical
settings.
KEY WORDS: Anticancer agents; peptidomimetics; drug design; enzyme inhibitors; irreversible inhib-
itors; reversible inhibitors; suicide inhibitors.
INTRODUCTION
The 26S proteasome
1 is a multifunctional ATP-
dependent proteolytic system that is responsible for
intracellular protein turnover (Goldberg et al., 1995;
Hochstrasser, 1995; Coux et al., 1996; Baumeister
and Lupas, 1997; Baumeister et al., 1998; Voges
et al., 1999). The enzymatic activity of this protease
complex occurs in a 700-KDa barrel-shaped core
structure known as the 20S proteasome (Coux et al.,
1996). This protein consists of four stacked rings
arrayed in an a7b7b7a7 manner (Groll et al., 1997;
Tanaka, 1998). Three b-subunits in each b-ring are
catalytically active and have an N-terminal threonine
as the active nucleophile involved in protein and
peptide proteolysis (Loewe et al., 1995). The protea-
some has at least three distinct peptidase activities
and, by comparison with substrate speciﬁcities of
known proteases, they are designated as: chymo-
trypsin-like (b5-subunit), trypsin-like (b2-subunit),
and peptidylglutamyl-peptide hydrolytic (PGPH)
activities (b1-subunit)
2 (Orlowski et al., 1993). The
involvement of the 20S proteasome in the ubiquitin
(Ub)-dependent and Ub-independent degradation of
critical regulatory proteins suggested a few years ago
the potential use of proteasome inhibitors as novel
therapeutic agents being applicable in many diﬀerent
disease indications (Elliott et al., 1999; Checler et al.,
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Adams, 2002). The speciﬁc target in the search for
novel cytotoxic and antiproliferative agents is the
chymotrypsin-like activity of the 20S proteasome.
Modulation of this enzymatic activity by b5-subunit-
speciﬁc inhibitors may convey an anti-tumor eﬀect by
induction of cell cycle arrest and apoptosis in tumor
cells.
3
Early synthetic proteasome inhibitors were rela-
tively nonspeciﬁc compounds but proved to be
valuable molecular probes for improving our under-
standing of biological processes associated with the
ubiquitin–proteasome pathway (Garcia-Echeverria,
2002). To overcome the inherent drawbacks of these
molecular probes, new classes of inhibitors that target
this proteolytic enzyme have emerged in the last few
years by natural product screening, and by combining
traditional drug discovery approaches with new
methods to ﬁnd and optimize lead structures. This
article reviews recent salient medicinal chemistry
achievements in the design, synthesis, and biological
characterization of both synthetic and natural pep-
tide-like proteasome inhibitors, updating recent re-
views on this class of agents (Garcia-Echeverria,
2002; Delcros et al., 2003; Groll and Huber, 2004).
As shown herein, diﬀerent compound classes are
capable of modulating the subunit-speciﬁc proteo-
lytic activities of the 20S proteasome in ways not
previously possible, and one of them, bortezomib,
has provided proof-of-concept for this therapeutic
approach in cancer clinical settings (Adams, 2001;
Chauhan et al., 2005; Mendoza et al., 2005; Mitsi-
ades et al., 2005; Zavrski et al., 2005).
The 20S proteasome modulators covered in this
manuscript are categorized in two broad groups,
covalent and non-covalent inhibitors, referring to the
ability of the compound to make an adduct with the
hydroxyl group of the N-terminal catalytic threonine
residue within the proteasome active site.
COVALENT INHIBITORS OF THE 20S
PROTEASOME
Boronic Acids and Esters
Peptide boronic acids and esters thereof that are
structural analogs of enzyme substrates have been
extensively employed as serine protease inhibitors,
most notably as thrombin inhibitors (Seufer-
Wasserthalet al.,1994;Couttset al.,1996;Martichonok
and Jones, 1996; Tian et al., 1997). It is assumed that
the activity of these compounds as reversible serine
protease inhibitors is due to an empty p-orbital on the
boronatomthatispositionedtoaccepttheoxygenlone
pair of the active site serine residue to form a stable,
nearly tetrahedral complex (Bone et al., 1987; Bone
et al., 1989). The unique nature of the boron/oxygen
interaction is also thought to provide selectivity for
serine proteases over cysteine proteases (Martichonok
andJones, 1997),owingtotheweaknature ofbonding
between the boron and the thiol group of the catalytic
cysteine of cysteine proteases. By analogy, it was pre-
sumedthatC-terminalboronic‘‘war-heads’’inpeptide
and derivative thereof could also form stable adducts
with the N-terminal threonine residues of the protea-
some active sites. A variety of peptide-like boronates
have been reported in the literature or covered in sev-
eral patents demonstrating the ability of the boronic
acid pharmacophore to modulate proteasome enzy-
matic activity.
Bortezomib (PS-341, LDP-341, Velcade ; Pro-
Script, now Millennium; compound 1, Figure 1) has
been the ﬁrst and probably the only 20S proteasome
inhibitor to enter clinical trials thus far (Chauhan
et al., 2005). This dipeptide boronic acid derivative is
a slow, tight-binding inhibitor of the chymotryptic
activity of the 20S proteasome (Ki = 0.6 nM) that
shows at least 500-fold selectivity over a series of en-
zymes (e.g., Ki = 2.3 lM, human leukocyte elastase;
Ki = 630 nM, human cathepsin G; Ki = 320 nM,
human chymotrypsin; and Ki =1 3lM, thrombin)
(Adams et al., 1998, 2000). Bortezomib showed anti-
tumor activity and prevented carcinoma metastases
alone and in combination with other standard anti-
cancer agents (e.g., ﬂuorouracil, gemcitabine, etopo-
side) or radiation in a variety of hematological
malignancies and solid tumor in mice models (e.g.,
prostate, colon and lung human xenografts). All
combination therapies were generally well tolerated.
In the case of multiple myeloma – the indication in
which the best results have so far been observed in the
clinic – the compound abrogated TNF-a induced
NF-jB activation and IL-6 secretion, and decreased
the binding of multiple myeloma cells to bone marrow
stromal cells. The compound passed all the preclinical
requirements, and a broad Phase I trial to asses its
maximum tolerated dose in several tumors was initi-
ated in 1998. Based largely on the results obtained in
Study 025 (response rate was 35%, including 10%
positive complete responses), the compound, which
was granted fast track statues for the treatment of
multiple myeloma in 2002, was approved in May 2003
by the US FDA for the treatment of patients with
50 Garcı´a-Echeverrı´arelapsed or refractory multiple myeloma – patients
that have previously been treated with conventional
chemotherapy alone or followed by high dose che-
motherapy and stem cell transplant (Chauhan et al.,
2005). The most clinically signiﬁcant toxicity was
cumulative dose-related peripheral sensory neuropa-
thy. At this moment, ongoing clinical trials are eval-
uating bortezomib in a variety of cancers, including
refractory metastatic colorectal cancers, non-small
cell lung cancers, lymphomas and leukemias. These
trials are expected to provide critical data to conﬁrm
the activity of this agent in a variety of cancers and to
clarify its potential adverse eﬀect proﬁle further.
In addition to bortezomib, other proteasome
inhibitors based on a boronic electrophile have been
reported (Siman et al., 1999; Gardner et al., 2000).
For example, signiﬁcant inhibition in B16 tumor
growth was observed in female C57BL mice after i.p.
administration of compound 2 (Figure 1) at
10 mg Kg
)1 day
)1 (Siman et al., 1999). This com-
pound is an analogue of CEP-1612 (Iqbal et al., 1995),
a C-terminal aldehyde peptidomimetic (see next
section).
To overcome some of the pharmaceutical limita-
tions inherent in peptides, hydrazino-azapeptoids
(Aubin et al., 2005) derivatives containing a reactive
boronic acid in a phenyl group (Figure 1) were syn-
thesized (e.g., compound 3, Figure 1; Ki =5 3lM,
chymotrypsin-like activity). In spite of having the
reactive ‘‘war-head’’ group, these peptidomimetics
have in general weak activity in inhibiting the chy-
motrypsin-like activity of the 20S proteasome, and
show modest antiproliferative activity against a panel
of tumor cell lines (IC50s ranging from 1–80 lM).
Although not supported with structural data, the low
aﬃnity of these boronic acid derivatives for the pro-
teasome was explained due to steric hindrance eﬀects,
but it is at this point unclear which of the structural
features of the molecule are involved in these negative
interactions.
Peptide Aldehydes, a-Keto Aldehydes, and a-Keto
Amides
The access to commercially available aldehydes
(e.g., the calpain inhibitors Ac-Leu-Leu-norlecucinal
and Ac-Leu-Leu-methional) (Wilk and Orlowski,
1983; Figueiredo-Pereira et al., 1994a) lead to the
early identiﬁcation and development of 20S protea-
some inhibitor containing this functional group. The
aldehyde forms a reversible covalent hemiacetal
intermediate with the hydroxyl group of the amino
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Peptide and Peptide-Like Modulators 51terminal threonine, suggestive of the tetrahedral
intermediate of a serine/cysteine protease reaction
(Lowe et al., 1995).
One of the major medicinal chemistry challenges
encountered with the early aldehyde derivatives was
selectivity and considerable eﬀort had to be expended
in overcoming this hurdle (Stein et al., 1983; Figuei-
redo-Pereira et al., 1994a, 1994b; Rock et al., 1994;
Iqbal et al., 1995; McCormack et al., 1998; Anma
et al., 1999; Mundy, 2000). A representative example
of the success achieved in this synthetic and drug
design endeavor is CEP-1612 (compound 4, Fig-
ure 2). This aldehyde is a potent and reversible
inhibitor of the chymotrypsin-like activity of the 20S
proteasome (IC50 = 2 nM) that does not block the
trypsin-like activity of this enzyme at concentrations
up to 1 lM (Iqbal et al., 1995), and exhibits 50-fold
selectivity against calpain and cathepsin B. CEP-1612
induces apoptosis in a panel of human tumor cell
lines. Tumor cell death is p53-independent and is
associated with accumulation of the cyclin-dependent
kinase inhibitors p21 and p27 (An et al., 1998). Other
peptide and peptoid aldehydes (compounds 5–10,
Figure 2) have been described in several patent
applications and publications to develop 20S pro-
teasome subunit speciﬁc inhibitors for the treatment
of cancer or other indications (e.g., inﬂammation,
autoimmune disorders) (Stein et al., 1997; Anma
et al., 1999; Loidl et al., 1999a, 1999b; Mundy, 2000;
Delcros et al., 2003). Of special scientiﬁc interest, it is
the 20S proteasome trypsin-like inhibitory selectivity
achieved with bifunctional inhibitors (compound 8,
Figure 2; IC50 = 0.5 lM, trypsin-like activity;
IC50>100 lM, chymotrypsin) (Loidl et al., 1999a).
These peptides contain a maleimido moiety to react
with the side chain of cysteine-118 in the S3 binding
pocket of the trypsin-like site, and a C-terminal
aldehyde group for hemicacetal formation with the
catalytic threonine residue. High potency against the
20S proteasome trypsin-like subunit was also ob-
tained by linking the N-terminus of two peptide
aldehydes with a polyoxyethylene spacer that is
appropriate for simultaneous binding at two active
sites (e.g., compound 9, Figure 2) (Loidl et al., 2000).
The bivalent inhibitor is two orders of magni-
tude more potent than the parent peptide alde-
hyde (IC50
trypsin-like = 0.071 lM for compound 9
versus IC50
trypsin-like = 6.4 lM for Ac-Arg-Val-Arg-
CHO). Although compounds 8 and 9 are good
examples of structure-based design, the reactivity of
the maleimido group towards thiols and the high
molecular weight of the bivalent inhibitors are
important pharmaceutical limitations and can restrict
the utility of these compounds only to cell-free
systems.
To overcome the poor stability of the aldehyde
group, a number of carbonyl replacements have been
developed. Thus, di- and tri-peptide a-keto aldehydes
(e.g., compounds 11 and 12, Figure 3), which are
slow-binding reversible inhibitors, were synthesized
as putative modulators of the chymotrypsin-like
activity of the 20S proteasome (Ki = 3.1 nM and
3.7 nM for 11 and 12, respectively). Along the same
theme of using an a-keto group, compound 13 (Fig-
ure 3) emerged as the most potent chymotrypsin-like
activity inhibitor (Ki = 1.1 nM) of a series of P’-ex-
tended a-keto amide derivatives. This compound
shows good selectivity over the trypsin-like activity of
the 20S proteasome and calpain 1 (>150-fold), and
reduces the in vivo growth of B16-FO murine mela-
noma tumors (Chatterjee et al., 1999; Chatterjee and
Mallamo, 1999). The a-keto amide moiety has also
been introduced at the N-terminus of lipophilic
peptides (compound 14,I C 50 =1lgm l
)1, bovine
20S proteasome; Figure 3), and exploited in hydraz-
ino aza and N-aza peptoids containing triﬂuorom-
ethyl, bromomethyl and cyanomethyl moieties
(Delcros et al., 2003).
Peptide Vinyl Sulfones and Esters
Another class of peptide-based inhibitors exploits
a vinyl sulfone moiety at the C-terminus. This group,
which was originally designed to target cysteine
proteases (Palmer, 1995), was expected to form an
irreversible covalent adduct with the hydroxyl group
of the catalytic threonine residue (Bogyo et al., 1997).
Conﬁrmation of this mechanism of action has been
obtained by solving the X-ray structure of the 20S
proteasome in complex with peptide vinyl sulfone
inhibitors (Groll et al., 2002).
Initial attempts with tri- and tetrapeptides vinyl
sulfones (compound 15; chymotrypsin-like activity
IC50 = 0.1–0.5 lM; trypsin-like and PGPH activities
IC50 =5 0 –100 lM; Figure 4) were directed to use
these peptides as probes to study substrate binding
and speciﬁcity of the proteasome (Bogyo et al., 1998).
Tothis end,the peptides were labeled with
125I to trace
binding to individual b-subunits by two-dimensional
gels. This study revealed that the P2–P4 substrate
positions are critical for directing the peptide sub-
strates to individual catalytic sites of the proteasome.
Incorporation of a number of aminohexanoic acid
spacersintothe(leucinyl)3-vinyl-(methyl)-sulfonecore
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Fig. 2. Peptide and peptoid aldehydes.
Peptide and Peptide-Like Modulators 53and N-terminal capping with bulky groups resulted in
cell-permeable derivatives with proteasome inhibitory
activity (compound 16, Figure 4) (Kessler et al.,
2001).
In addition to sulfones, the vinyl group has been
used in conjunction with esters (Marastoni et al.,
2005). The incorporation of the ethyl acrylate group
at the C-terminus of tripeptide-based compounds has
resulted in potent and selective inhibitors of the
trypsin-like activity (e.g., compound 17;I C 50 =
0.041 lM, trypsin-like; IC50 = 4.21 lM, chymo-
trypsin-like; and IC50>10lM, PGPH; Figure 4).
Enzymatic dilution experiments indicate irreversible
inhibition of the enzyme suggesting that the ethyl
acrylate group functions as a substrate of the cata-
lytic threonine. As expected from the in vitro activity
proﬁle, the compounds showed negligible tumor cell
antiproliferative activity (IC50>10lM), but were
able to modulate the generation and presentation of
the subdomain CLG epitope in cellular settings
(HLA-A2-positive RG lymphobastoid cells).
5-Methoxy-1-Indanone Dipeptide Benzamides
An alternative to the traditional electrophilic head
groups used to target serine proteases is the 5-meth-
oxy-1-indanone moiety. This group, which can be
considered less reactive but hydratable, was incorpo-
rated at the N-terminus of a series of dipeptide
derivatives (e.g., compound 18–20, Figure 5) (Lum
et al., 1998b) to target the chymotrypsin-like activity
of the 20S proteasome (IC50 = 0.20 and 0.10 lM for
18 and 19, respectively), but they show modest anti-
proliferative activity in cellular assays (IC50 =8lM,
RAW cells, murine macrophage cell line) (Lum et al.,
1998a, b). Inhibition of activation of NF-jB in vitro
and lipopolysaccharide-induced tumor necrosis factor
synthesis in RAW cells have also been described for
this compounds class (Lum et al., 1998a).
Natural Products and Derivatives Thereof
Proteasome inhibitors from natural sources have
been intensively pursued both as molecular probes of
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54 Garcı´a-Echeverrı´athe proteasome biology and as potential therapeutic
agents. Representative examples of natural products
that have been described as proteasome inhibitors in
the past few years are brieﬂy reported in this section.
Natural products containing an a¢,b¢-epoxyketone
pharmacophore group and a liner peptide backbone
have exhibited potent proteasome inhibitory activity
in biochemical and cellular settings. Dihydroepone-
mycin (compound 21, Figure 6) (Sugawara et al.,
1990; Oikawa et al., 1998) inhibits competitively
and irreversibly the enzymatic activities of the b1, b2,
and b5 subunits of the 20S proteasome, but at dif-
ferent rates (Meng et al., 1999); thus, inhibition of the
chymotrypsin-like (kassociation = 66.4±8.9 M
)1 s
)1)
and PGPH activities (kassociation = 60.5±8.8
M
)1 s
)1) proceeded more than 10-fold faster than
inhibition of the trypsin-like activity (kassociation =
4.4±0.4 M
)1 s
)1). Moreover, this natural product
does not inhibit calpain and trypsin, although minor
inhibition is observed against cathepsin B and chy-
motrypsin at higher concentration. Another example
of a proteasome inhibitor containing an a¢,b¢-ep-
oxyketone group is epoxomicin (compound 22,F i g -
ure 6) (Hanada et al., 1992), which is a natural
peptide isolated from the actinomycete strain No.
Q996-17. This compound potently and irreversibly
inhibits the chymotrypsin-like (kobs/[I] =
37,200 M
)1 s
)1) activity of the 20S proteasome, and
to a lesser extent the trypsin-like (kobs/
[I] = 287 M
)1 s
)1) and PGPH activities (kobs/
[I] = 34 M
)1 s
)1) of this protease complex. Interest-
ingly, and unlike most other proteasome inhibitors,
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Peptide and Peptide-Like Modulators 55epoxomicin did not inhibit papain, chymotrypsin,
trypsin, cathepsin B or calpain at concentrations up to
50 lM. The ﬁrst insights into its mechanism of action
and high selectivity for the proteasome were obtained
by solving the X-ray structure of epoxomicin in
complex with the yeast S. cerevisiae 20S proteasome
(Groll et al., 2000). The structure revealed the pres-
ence of an unexpected morpholino ring derived from
the interaction of the a¢,b¢-epoxyketone pharmaco-
phore of epoxomicin with the N-terminal Thr Oc and
N atoms. The occurrence of the morpholine derived
adduct is also supported by mass spectrometric
analysis (Groll et al., 2000). Additional natural
products containing an a¢,b¢-epoxyketone moiety
have been obtained by culturing Streptomyces (e.g.,
compound 23, Figure 6), and this reactive group has
also been exploited in the design and synthesis of
epoxomicin-like proteasome inhibitors (compound
24–25, Figure 6) (Elofsson et al., 1999; Kim et al.,
1999).
Lactacystin (compound 26, Figure 7) is an irre-
versible, covalent inhibitor of the chymotrypsin-like
and trypsin-like activities and a weak, reversible
inhibitor of the PGPH activity of the 20S proteasome
(Fenteany et al., 1996; Omura and Takeshima, 1996;
Omura and Tomoda, 1996; Ostrowska et al., 1997).
This natural product, which is a Streptomyces
metabolite (Omura et al., 1991a, 1991b) undergoes in
solution a spontaneous conversion – lactonization –
to the active proteasome inhibitor, clasto-lactacystin
b-lactone also known as omuralide. (compound 27,
Figure 7), which is the active compound that deacti-
vates the 20S proteasome (Dick et al., 1996; Fenteany
et al., 1996). The acylation of the N-terminal threo-
nine b5 subunit of the 20S proteasome by the reactive
clasto-lactacystin b-lactone has been conﬁrmed by
X-ray crystallography studies (Groll et al., 1997).
Furthermore, in vitro experiments with radiolabelled
lactacystin in whole cells have shown that almost all
the radioactivity becomes associated with the pro-
teasome, demonstrating a remarkable speciﬁcity for
that entity over a very large number of other proteins.
In spite of these experimental results, lactacystin is
not absolutely speciﬁc for the proteasome, as it has
been reported to inhibit other enzymes (Geier et al.,
1999).
A substantial eﬀort was devoted to the total
synthesis of lactacystin, and the successful identiﬁ-
cation of diﬀerent synthetic routes (Corey and Rei-
chard, 1992; Corey et al., 1993; Sunazuka et al.,
1993; Uno et al., 1994; Chida et al., 1995; Nagamitsu
et al., 1996; Chida et al., 1997; Corey et al., 1998;)
allowed the preparation of lactacystin analogs (e.g.,
compound 28, Figure 7) (Soucy et al., 1999) and
initial studies on the molecular basis of its selectivity
and potency (Corey et al., 1999). The initial SAR
data revealed that the original groups at C5 and C9
seem to be optimal for proteasome inhibition and
only the replacement of the 7-methyl substituent by
ethyl, n-butyl or isopropyl improved 2- to 2.8-fold the
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56 Garcı´a-Echeverrı´achymotrypsin-like peptidase inhibitory activity of the
parent compound.
A structurally related analogue of clasto-lactacy-
stin b-lactone is salinosporamide A (NPI-0052;
compound 29, Figure 7), a compound isolated from
the Marine Actinomycete Salinispora tropica. This
natural product is a potent and selective inhibitor of
the proteasome (Feling et al., 2003) that exhibits low
nM IC50 values against a broad panel of tumor cell
lines (e.g., MDA-MB435 and SK-MEL28, IC50<
11 nM) (Feling et al., 2003; Williams et al., 2005).
Interestingly, salinosporamide A did show potent
activity when tested in antimicrobial and antiviral
assays. Cellular SAR data obtained with seven
related salinosporamide analogs indicate that the
b-lactone and the cloroethyl group of salinospora-
mide A are key pharmacophores for this compound
class. Further conﬁrmation of these initial observa-
tions was obtained by testing a series of ana-
logues generated through fermentation or synthetic
derivatization in biochemical and cellular assays
(Macherla et al., 2005). Thus, marked reductions in
potency, particularly in cellular settings (3 to 2-logs),
accompanied the replacement of the cloroethyl group
with unhalogenated alkyl substituents. The in vitro
SAR data did not provide a clear understanding of
the potential mechanistic role of the halogen and,
probably, additional studies and the resolution of the
X-ray structure of salinosporamide A complexed
with the 20S proteasome will be required to clarify
this interesting point.
Recently, the synthesis and biological character-
ization of an omuralide–salinosporin hybrid has been
reported (Reddy et al., 2005). The synthetic hybrid
(compound 30, Figure 7) is about 2.5 times more
potent than oromulide in inhibition of the chymo-
trypsin-like activity of the 20S proteasome, and it is
slightly less potent than salisnosporamide A.
Tyropeptin A and B (compounds 31 and 32,
Figure 8) are proteasome inhibitors isolated from
Kitasatospora sp. MK993-dF2 (Momose et al.,
2001a, b). They inhibit the chymotrypsin-like activity
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Peptide and Peptide-Like Modulators 57and trypsin-like activities of the 20S proteasome
with IC50 values of 0.1/1.5 and 0.2/4.0 lgm l
)1,
respectively. No inhibition of the PGPH activity is
observed at concentration of 100 lgm l
)1. Other
enzymes (e.g., chymotrypin, cathepsin L, and
m-calpain) are also inhibited by these natural pep-
tides. To increase its potency, a structural model of
tyropeptin A bound to the chymotrypsin-like
activity site of the mammalian 20S proteasome was
constructed. Analyses of the interactions of the
inhibitor with the protein identiﬁed an open space
in the vicinity of the N-terminus of tyropeptin A.
The possibility to increase inhibitory activity by
increasing the number of van der Waals interac-
tions with the protein fueled the synthesis of a
series of analogues containing bulky N-terminal
moieties (Momose et al., 2005). This synthetic eﬀort
resulted in the identiﬁcation of TP-110 (compound
33, Figure 8), which inhibits the chymotrypsin-like
activity of the 20S proteasome with an IC50 value
of 0.027 lM and shows an excellent selectivity over
the other two catalytic sites (IC50>100 lM). No
data have been provided so far on the anticancer
activity of TP-110 or derivatives thereof.
Belactosin A (compound 34, Figure 9) is a
Streptomyces metabolite (KY11780) identiﬁed in a
yeast based assay (Asai et al., 2000) that has been
reported to block 20S proteasome activity in
biochemical assays (IC50 = 0.4 lM, chymotrypsin-
like).StructuralfeaturesofbelactosinA–inparticular,
the b-lactone and the 3-(2-aminocyclopropyl)-alanine
moiety – were exploited in the design of a new class
of proteasome inhibitors (e.g., KF33955; compound
35, Figure 9; IC50 = 0.04 lM, chymotrypsin) that
showed in vivo activity in tumor bearing animals
(T/C of 49% in nude mice implanted with WiDr
tumor xenografts) (Yamaguchi et al., 2000).
Recently, the enantioselective total synthesis of
belactosin A, C and its homo-analogue has been
reported (Larionov and de Meijere, 2004).
NON-COVALENT 20S PROTEASOME
INHIBITORS
Non-covalent inhibitors of the proteasome seem
to have been investigated less extensively judging
from the paucity of reports on this type of com-
pounds. In principle, such inhibitors should be devoid
of the inherent drawbacks often associated with the
reactive groups – lack of speciﬁcity, excessive reac-
tivity and instability – used for the establishment of
the covalent interaction. This section highlights key
achievement in the identiﬁcation and development of
20S proteasome inhibitors that do not covalently
modify the protein.
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Analogs
A series of 2-aminobenzylstatine derivatives,
which were originally designed to target the HIV-1
protease, have shown proteasome-inhibitory activity
in biochemical assays (Furet et al., 2001; Garcı´a-
Echeverrı´a et al., 2001). Compound 36 (Figure 10)
was identiﬁed by HTS and represented one of the ﬁrst
non-covalent proteasome inhibitors reported in the
literature. This compound inhibits the chymotrypsin-
like activity of the 20S proteasome with an IC50 value
of 0.9 lM and shows good selectivity over the
trypsin-like and PGPH activities (IC50>20lM).
The active site responsible for the chymotrypsin-like
proteolytic activity of the human 20S proteasome is
formed by the association of b-subunits X and HC5.
Exploiting the X-ray crystal structure of the yeast
proteasome, a structural model of the preceding
b-subunits was constructed (Furet et al., 2001). The
model served to understand the structural basis of its
inhibitory activity and to guide the medicinal chem-
istry optimization of this class of non-covalent
inhibitors. According to this model, which was sup-
ported by extensive structure-activity relationships, a
large number of complementary hydrophobic and
hydrogen bond interactions between the inhibitor
and the S1 and S3 pockets of the enzyme may
account for the ability of this class of inhibitors to
inhibit selectivity of the chymotrypsin-like activity
site of the human 20S proteasome without forming
an adduct with the catalytic threonine residue. The
homology model in conjunction with a modular
chemistry strategy was used to improve the inhibitory
activity of the original hit (Garcı´a-Echeverrı´a et al.,
2001; Furet et al., 2002). A major boost in activity
N
H
N
H
N
H
H
O
O
O
O
O
N
H
N
H
N
H
H
O
O
O
O
O
OH
N
H
N
H
N
H
H
O
O
O
O
O
O
Tyropeptin A
31
Tyropeptin B
32
TP-110
33
Fig. 8. Tyropeptin A and B, and a synthetic analogue.
N
H
O
O O
O O
N
H
O
N H2
N H2
N
H
O
N
H
O OH
O
O O
Belactosin A
34
KF33955
35
Fig. 9. Belactosin A and a synthetic analogue.
Peptide and Peptide-Like Modulators 59was obtained by improving the interactions of the
benzylamino group of the inhibitor with the side
chains of Ser 157 and Tyr 135 in the S3 pocket of
the enzyme. Compound 37 (Figure 10) that can form
the targeted hydrogen bond interactions with the
preceding residues inhibits the chymotrypsin-like
activity of the human 20S proteasome with an IC50
value of 0.05 lM. Parallel to the optimization of the
central motif, the possibility of enhancing potency by
creating additional van der Waals interactions with a
small cavity accessory pocket near the S3 binding site
was explored by modifying the N-terminus of com-
pound 37. The replacement of the original benzyl-
oxycarbonyl group by naphthalene-1-yl-acetic acid
improved substantially the inhibitory potency
(IC50 = 0.007 lM) of the new peptidomimetic
(compound 38, Figure 10). The chemical modiﬁca-
tions introduced in the original hit did not aﬀect the
speciﬁcity proﬁle of this class of inhibitors. Thus,
compound 38 has a modest activity against the
trypsin-like and PGPH activities of the 20S protea-
some (IC50>20lM). However, and despite of the
potency and selectivity observed in biochemical
assays, compound 38 did not show good activity in
cellular settings (e.g., IC50 = 1.5 lM, inhibition of
proliferation of MDA-MB-435 cells). Assuming that
poor cellular permeability was the main reason for
the modest cellular activity of these 2-aminobenzyls-
tatine derivates, the SAR data generated during the
optimization of this compound class and the binding
model were exploited to design an alternative inhib-
itor scaﬀold with reduced size and attenuated pep-
tidic character (Furet et al., 2004). The starting
hypothesis was that the two amide bonds ﬂanking the
tert-leucine amino acid and the statine 4-benzyl group
have no signiﬁcant interactions with the enzyme. A
representative example of this design strategy is
compound 39 (Figure 10). In this new scaﬀold, the
non-productive structural features have been re-
moved and the critical interactions of the 2-amino-
benzylstatine inhibitors have been incorporated or
mimicked. Thus, the two amide bonds ﬂanking the
valine residue and the C-terminal benzylamide group
ﬁlling the S1 pocket are conserved whereas the statine
moiety is replaced by a non-proteinogenic residue
-3,4,5-trimethoxy-L-phenylalinine-, which is able to
mimic the interactions with the S3 pocket. The tert-
leucine side chain and the hydrophobic N-terminal
group are mimicked by a single phenoxy substituted
benzylic synthon. Overall, the high potency and
selectivity of compound 38 were matched by com-
pound 39 in biochemical assays: IC50 =1 5n M ,
chymotrypsin-like activity and IC50>20lM, tryp-
sin-like and PGPH proteolytic activities. However,
and in contrast to compound 38, compound 39 also
showed good activity in cellular settings. Thus, it
blocks proteasome activity in cultured cells
(IC50 = 20 nM) and inhibits in a dose-dependent
manner the proliferation of diﬀerent cell lines (e.g.,
IC50 = 60 nM, MDA-MB-435 cells).
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Ritonavir (compound 40, Figure 11) is a potent
inhibitor of the human immunodeﬁciency virus
(HIV)-1 protease and is clinically applied to sup-
press HIV-1 replication in AIDS patients. In addi-
tion to its biological activity against its original
target, it inhibits in vitro the chymotrypsin-like
activity of the 20S proteasome while the trypsin-like
activity is markedly enhanced (Andre et al., 1998;
Schmidtke et al., 1999). Kinetic studies revealed that
the eﬀect on the trypsin-like enzymatic activity is
due to binding of ritonavir to a non-catalytic
modiﬁer site (Schmidtke et al., 1999). Apart from
ritonavir, saquinavir also inhibits the chymotrypsin-
like activity of the 20S proteasome although much
less eﬃciently. Other HIV-1 inhibitors like indinavir
or nelﬁnavir do not aﬀect 20S proteasome activity
(Andre et al., 1998).
Arecoline Tripeptides
Although originally designed as potential covalent
inhibitors, arecoline tripeptides seem to inhibit the
human proteasome in biochemical assays (e.g., com-
pound 41, Figure 11; IC50 = 0.52 lM, chymotryp-
sin-like site) without forming an adduct with the
protein (Marastoni et al., 2004). The arecoline moi-
ety, which could act as a Michael substrate for the
catalytic threonine, did not improve the inhibi-
tory activity of reference compounds when introduced
at the C-terminus, but proved to be beneﬁcial when
incorporated at the N-terminus of selected sequences.
The active arecoline peptides inhibit 20S proteasome
in cellular settings with activities similar to the ones
obtained in the biochemical assays, and have good
stability in culture media (t1/2>360 min).
Macrocycle Peptides
A series of 17-membered macrocycle peptides
(TMC-95A, -B, -C, and -D) isolated from the fer-
mentation broth of Apiospora montagnei Sacc.
TC1093 have been shown to potently inhibit the
proteasome in biochemical assays (e.g., TMC-95A,
compound 43,I C 50 = 5.4, 200 and 60 nM for the
chymotrypsin-like, trypsin-like and PGPH activities,
respectively; Figure 11) (Koguchi et al., 2000). The
biological proﬁle of TMC-95A elicited a great
interest in the scientiﬁc community and several
groups have reported diﬀerent synthetic approaches
to prepare this natural product and synthetic ana-
logues thereof (Lin and Danishefsky, 2002; Berthelot
et al., 2003; Inoue et al., 2003). The X-ray structure
of the yeast proteasome in complex with TMC-95A
revealed multiple hydrogen-bond interactions be-
tween the inhibitor and the protein that, in the ab-
sence of a covalent bond, may contribute to the
high-aﬃnity binding with the protein. In the struc-
ture, the n-propyline group protudes into the S1
pocket and the side chain of asparagine is inserted
deeply into the S3 pocket. This last interaction is
believed to play a major role in the selectivity of
TMC-95A over other enzymes (e.g., IC50>30lM
for m-calpain, cathepsin L and trypsin). Further-
more, synthetic activities around the TMC-95A
skeleton have shown that not all of the elements of
the natural product are required for proteasome
inhibition (Kaiser et al., 2002), and that simpler
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Peptide and Peptide-Like Modulators 61compounds with improved aﬃnity and selectivity
could be identiﬁed and developed.
Allosteric Inhibitors
Atomic force microscopy and in vitro 26S protea-
some assembly experiments have shown that PR39, a
natural 39-mer antibacterial peptide (RRRPRPPYLP
RPRPPPFFPPRLPPRIPPGFPPRFPPRFP), inter-
feres with the conformation of both 20S and 26S
proteasomes leading to inhibition of its peptidase
activities (e.g., Ki = 25 nM, chymotrypsin-like activ-
ity) (Gaczynska et al., 2003). Although the possibility
of contacts with sites on the 19S particles are not ruled
out, it seems that the N-terminal arginine residues of
this non-competitive and reversible inhibitor interacts
with the acidic tail of the non-catalytic subunit a7
perturbing the ‘‘normal’’ conformational dynamics
of the enzyme. Biological evaluation of truncated
peptides of PR39andalanine scans identiﬁed RRRPR
PPYLPR as the shortest functional sequence.
CONCLUSIONS AND OUTLOOK
As shown in the preceding sections, a variety of
synthetic and natural inhibitors are capable of
modulating the subunit-speciﬁc enzymatic activities
of the 20S proteasome complex in ways not previ-
ously possible. Retrospectively, it seems that the
transition from the original peptide-like molecules to
potential drug candidates has proved rather diﬃcult
and has been meet with limited success. Even if some
of the new 20S proteasome modulators have both in
vitro and in vivo activity against a variety of cancer
cell lines and tumor xenografts in preclinical studies
(Adams, 2004), only one 20S proteasome inhibitor
has so far entered clinical trials and received approval
by the health authorities for the treatment of patients
with relapsed and refractory multiple myeloma.
Overall, we can conclude from the current preclinical
and clinical information that the introduction of
proteasome inhibitors as potential anticancer drugs is
still in an early stage. Deﬁnitely, the clinical eﬃcacy
of 20S proteasome modulators in other malignancies
besides multiple myeloma is eagerly awaited.
NOTES
1. The 26S proteasome is formed by the 20S
proteasome capped by another multimeric compo-
nent called the 19S complex or PA700.
2. This catalytic site is also termed post-acidic
or caspase-like activity.
3. It has been shown that malignant cells are
more susceptible to the pro-apoptotic eﬀects of pro-
teasome inhibition than normal cells.
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